Gilead Sciences Inc
GILDToday
-0.15%
5 Days
+3.65%
1 Month
+15.39%
6 Months
+6.20%
Year to Date
+24.53%
1 Year
+34.66%
Recent
Analysis
Gilead Sciences Inc Stock (GILD) Moved Up by 3.66% on Aug 19: A Full Analysis
• Gilead raised full-year sales guidance driven by accelerated HIV portfolio growth. • A federal court injunction blocked foreign importation to protect core market share. • Analysts issued Buy ratings with an average price target of $157.79.
Gilead Sciences Inc Stock (GILD) Moved Up by 3.14% on Aug 18: Drivers Behind the Movement
• A federal court injunction blocks foreign importation of Gilead's key HIV medications. • Robust base-business revenue growth and raised guidance drove positive market sentiment. • Strategic oncology investments and bullish institutional options activity supported equity momentum.
Mckesson Corp Stock (MCK) Closed Up by 5.08% on Aug 5: What Investors Need To Know
• McKesson reported fiscal first-quarter earnings exceeding consensus expectations across core metrics. • Management raised full-year earnings guidance, citing strength in oncology and biopharma services. • The company leads its industry with $403.43 billion in latest annual revenue.
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.10% on Aug 5: Key Drivers Unveiled
• Bristol-Myers Squibb lowered its financial outlook due to high costs replacing aging drugs. • Investors are concerned about slow adoption rates for the company's new product launches. • Federal drug pricing negotiations create valuation uncertainty and a price ceiling for shares.
Amgen Inc Stock (AMGN) Moved Up by 4.57% on Aug 5: Drivers Behind the Movement
• Amgen shares rose following strong quarterly earnings and increased full-year guidance. • Positive clinical trial updates for the obesity drug MariTide boosted investor confidence. • Analysts raised price targets citing improved margins and robust product portfolio growth.
Gilead Sciences Inc Stock (GILD) Moved Down by 3.96% on Aug 5: A Full Analysis
• Gilead Sciences shares fell after lowering its full-year earnings guidance. • Decelerating HIV franchise sales and lackluster oncology clinical results impacted investor sentiment. • Increased operational and research costs compressed the company's profit margins.
Gilead Sciences Inc's Score
Media Coverage
Analyst Rating
Gilead Sciences Inc Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
Gilead Sciences Inc Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.50% |
| BlackRock Institutional Trust Company, N.A. | 6.11% |
| State Street Investment Management (US) | 4.85% |
| Fidelity Management & Research Company LLC | 4.75% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 56.35% |
| Investment Advisor/Hedge Fund | 24.99% |
| Research Firm | 2.97% |
| Pension Fund | 2.97% |
Related Instruments
Popular Instruments
